Nitric oxide (NO) releasing poly ADP-ribose polymerase 1 (PARP-1) inhibitors targeted to glutathione S-transferase P1-overexpressing cancer cells

Journal of Medicinal Chemistry

Volumn 57, Issue 6, 2014, Pages 2292-2302

  Maciag, Anna E ^a   Holland, Ryan J ^b   Kim, Youseung ^b   Kumari, Vandana ^b   Luthers, Christina E ^b   Sehareen, Waheed S ^b   Biswas, Debanjan ^b   Morris, Nicole L ^a   Ji, Xinhua ^b   Anderson, Lucy M ^b   Saavedra, Joseph E ^a   Keefer, Larry K ^b  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE; GLUTATHIONE TRANSFERASE P1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NITRIC OXIDE; OLAPARIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CHEMICAL REACTION; CONTROLLED STUDY; CROSS LINKING; DNA DAMAGE; DNA REPAIR; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; COMET ASSAY; DNA DAMAGE; DRUG DESIGN; DRUG SYNERGISM; ENZYME INHIBITORS; GLUTATHIONE S-TRANSFERASE PI; HUMANS; ISOENZYMES; MODELS, MOLECULAR; NEOPLASMS; NITRIC OXIDE; POLY(ADP-RIBOSE) POLYMERASES; PRODRUGS; PYRAZINES; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897454666     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401550d     Document Type: Article

References (27)

1. Samol, J.; Ranson, M.; Scott, E.; Macpherson, E.; Carmichael, J.; Thomas, A.; Cassidy, J. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study Invest. New Drugs 2012, 30, 1493-1500
2. Khan, O. A.; Gore, M.; Lorigan, P.; Stone, J.; Greystoke, A.; Burke, W.; Carmichael, J.; Watson, A. J.; McGown, G.; Thorncroft, M.; Margison, G. P.; Califano, R.; Larkin, J.; Wellman, S.; Middleton, M. R. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours Br. J. Cancer 2011, 104, 750-755
3. Rajan, A.; Carter, C. A.; Kelly, R. J.; Gutierrez, M.; Kummar, S.; Szabo, E.; Yancey, M. A.; Ji, J.; Mannargudi, B.; Woo, S.; Spencer, S.; Figg, W. D.; Giaccone, G. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors Clin. Cancer Res. 2012, 18, 2344-2351
4. Shami, P. J.; Saavedra, J. E.; Wang, L. Y.; Bonifant, C. L.; Diwan, B. A.; Singh, S. V.; Gu, Y.; Fox, S. D.; Buzard, G. S.; Citro, M. L.; Waterhouse, D. J.; Davies, K. M.; Ji, X.; Keefer, L. K. JS-K, a glutathione/glutathione S-transferase activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity Mol. Cancer Ther. 2003, 2, 409-417
5. 2-aryl diazeniumdiolates in vitro and in vivo J. Med. Chem. 2006, 49, 4356-4366
6. Kiziltepe, T.; Hideshima, T.; Ishitsuka, K.; Ocio, E. M.; Raje, N.; Catley, L.; Li, C. Q.; Trudel, L. J.; Yasui, H.; Vallet, S.; Kutok, J. L.; Chauhan, D.; Mitsiades, C. S.; Saavedra, J. E.; Wogan, G. N.; Keefer, L. K.; Shami, P. J.; Anderson, K. C. JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells Blood 2007, 110, 709-718
7. Maciag, A. E.; Chakrapani, H.; Saavedra, J. E.; Morris, N. L.; Holland, R. J.; Kosak, K. M.; Shami, P. J.; Anderson, L. M.; Keefer, L. K. The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species J. Pharmacol. Exp. Ther. 2011, 336, 313-320
8. Nandurdikar, R. S.; Maciag, A. E.; Holland, R. J.; Cao, Z.; Shami, P. J.; Anderson, L. M.; Keefer, L. K.; Saavedra, J. E. Structural modifications modulate stability of glutathione-activated arylated diazeniumdiolate prodrugs Bioorg. Med. Chem. 2012, 20, 3094-3099
9. Weyerbrock, A.; Osterberg, N.; Psarras, N.; Baumer, B.; Kogias, E.; Werres, A.; Bette, S.; Saavedra, J. E.; Keefer, L. K.; Papazoglou, A. JS-K, a glutathione S-transferase-activated nitric oxide donor with antineoplastic activity in malignant gliomas Neurosurgery 2012, 70, 497-510
10. Menear, K. A.; Adcock, C.; Boulter, R.; Cockcroft, X. L.; Copsey, L.; Cranston, A.; Dillon, K. J.; Drzewiecki, J.; Garman, S.; Gomez, S.; Javaid, H.; Kerrigan, F.; Knights, C.; Lau, A.; Loh, V. M., Jr.; Matthews, I. T.; Moore, S.; O'Connor, M. J.; Smith, G. C.; Martin, N. M. 4-[3-(4- Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2 H -phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1 J. Med. Chem. 2008, 51, 6581-6591
11. Saavedra, J. E.; Srinivasan, A.; Buzard, G. S.; Davies, K. M.; Waterhouse, D. J.; Inami, K.; Wilde, T. C.; Citro, M. L.; Cuellar, M.; Deschamps, J. R.; Parrish, D.; Shami, P. J.; Findlay, V. J.; Townsend, D. M.; Tew, K. D.; Singh, S.; Jia, L.; Ji, X.; Keefer, L. K. PABA/NO as an anticancer lead: analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity J. Med. Chem. 2006, 49, 1157-1164
12. 2-arylated bis-diazeniumdiolate "double JS-K" Chem. Res. Toxicol. 2012, 25, 2670-2677
13. Maciag, A. E.; Holland, R. J.; Cheng, R. Y-S.; Rodriguez, L. G.; Saavedra, J. E.; Anderson, L. M.; Keefer, L. K. Nitric oxide-releasing prodrug triggers cancer cell death through deregulation of cellular redox balance Redox Biol. 2013, 1, 115-124
14. Adams, J.; Palombella, V. J.; Sausville, E. A.; Johnson, J.; Destree, A.; Lazarus, D. D.; Maas, J.; Pien, C. S.; Prakash, S.; Elliott, P. J. Proteasome inhibitors: a novel class of potent and effective antitumor agents Cancer Res. 1999, 59, 2615-2622
15. Ling, Y. H.; Liebes, L.; Ng, B.; Buckley, M.; Elliott, P. J.; Adams, J.; Jiang, J. D.; Muggia, F. M.; Perez-Soler, R. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis Mol. Cancer Ther. 2002, 1, 841-849
16. Ling, Y. H.; Liebes, L.; Jiang, J. D.; Holland, J. F.; Elliott, P. J.; Adams, J.; Muggia, F. M.; Perez-Soler, R. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines Clin. Cancer Res. 2003, 9, 1145-1154
17. Mortenson, M. M.; Schlieman, M. G.; Virudachalam, S.; Bold, R. J. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line Cancer Chemother. Pharmacol. 2004, 54, 343-353
18. Yang, Y.; Ikezoe, T.; Saito, T.; Kobayashi, M.; Koeffler, H. P.; Taguchi, H. Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling Cancer Sci. 2004, 95, 176-180
19. Denlinger, C. E.; Rundall, B. K.; Jones, D. R. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species J. Thorac. Cardiovasc. Surg. 2004, 128, 740-748
20. Jones, D. R.; Moskaluk, C. A.; Gillenwater, H. H.; Petroni, G. R.; Burks, S. G.; Philips, J.; Rehm, P. K.; Olazagasti, J.; Kozower, B. D.; Bao, Y. Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer J. Thorac. Oncol. 2012, 7, 1683-1690
21. Ling, Y. H.; Liebes, L.; Zou, Y.; Perez-Soler, R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells J. Biol. Chem. 2003, 278, 33714-33723
22. NAr reactions J. Org. Chem. 2001, 66, 3090-3098
23. Saavedra, J. E.; Booth, M. N.; Hrabie, J. A.; Davies, K. M.; Keefer, L. K. Piperazine as a linker for incorporating the nitric oxide-releasing diazeniumdiolate group into other biomedically relevant functional molecules J. Org. Chem. 1999, 64, 5124-5131
24. Romanowska, M.; Maciag, A.; Smith, A. L.; Fields, J. R.; Fornwald, L. W.; Kikawa, K. D.; Kasprzak, K. S.; Anderson, L. M. DNA damage, superoxide, and mutant K-ras in human lung adenocarcinoma cells Free Radical Biol. Med. 2007, 43, 1145-1155
25. Ji, X.; Pal, A.; Kalathur, R.; Hu, X.; Gu, Y.; Saavedra, J. E.; Buzard, G. S.; Srinivasan, A.; Keefer, L. K.; Singh, S. V. Structure-based design of anticancer prodrug PABA/NO Drug Des. Dev. Ther. 2008, 2, 123-130
26. Prade, L.; Huber, R.; Manoharan, T. H.; Fahl, W. E.; Reuter, W. Structures of class pi glutathione S-transferase from human placenta in complex with substrate, transition-state analogue and inhibitor Structure 1997, 5, 1287-1295
27. MacroModel, version 9.6; Schrödinger, LLC: New York, NY, 2008.